Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Shrimanker (Oxford, United Kingdom), K. Borg (Oxford, United Kingdom), C. Connolly (Oxford, United Kingdom), S. Thulborn (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), L. Xue (Oxford, United Kingdom), G. Hynes (Oxford, United Kingdom), T. Hinks (Oxford, United Kingdom), M. Kots (Parma, Italy), L. Girardello (Verona, Italy), S. Petruzzelli (Verona, Italy), J. Steiner (Oxford, United Kingdom), S. Vinall (Abingdon, United Kingdom), M. Hunter (Abingdon, United Kingdom), R. Pettipher (Abingdon, United Kingdom), I. Pavord (Oxford, United Kingdom). Late Breaking Abstract - Effect of timapiprant, a DP2 antagonist, on airway inflammation in severe eosinophilic asthma. 3784

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract: Inhaled pitrakinra, an IL-4/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma. Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract - A GATA3-specific DNAzyme attenuates sputum eosinophilia in COPD patients with eosinophilic airway inflammation Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - An assessment of potential predictive biomarkers for the treatment of severe eosinophilic asthma with CRTH2 antagonists Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 LATE-BREAKING ABSTRACT: Effects of a dual CysLT1/2 antagonist, ONO-6950, on allergen-induced airway responses in subjects with mild allergic asthma. Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Late Breaking Abstract - Role of Muscarinic M3 receptors in bronchial remodelling of severe asthma Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017 Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Gender and asthma: Gender-dependent effects of obesity on allergic pulmonary inflammation Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Markers of eosinophilic airway inflammation in patients with severe and mild to moderate asthma Source: International Congress 2016 – Airway biomarkers Year: 2016 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Modulation of inflammation by benralizumab in eosinophilic airway disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Eosinophilic inflammation amplifies the prednisolone-induced prothrombotic state in asthma Source: International Congress 2016 – Inflammatory biomarkers in airway diseases Year: 2016 Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Late Breaking Abstract: Persistent effect of bronchial thermoplasty (BT) in severe asthma at two years Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Improved effects of formoterol-budesonide combination on residual eosinophilic inflammation in asthmatic peripheral airway Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Expression of nasal and bronchial IL-17F and related cytokines in frequent exacerbators with neutrophilic severe asthma Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016